$792 Million is the total value of Avoro Capital Advisors LLC's 47 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 36.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | Sell | TESARO INC | $56,000,000 | -11.6% | 400,403 | -2.8% | 7.07% | -12.6% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $45,482,000 | -12.2% | 500,789 | -15.1% | 5.74% | -13.2% |
| MDCO | Sell | MEDICINES CO | $42,157,000 | -27.2% | 1,109,100 | -6.4% | 5.32% | -28.1% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $17,130,000 | -69.4% | 614,200 | -62.3% | 2.16% | -69.8% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $13,174,000 | -41.5% | 140,700 | -60.2% | 1.66% | -42.2% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $12,538,000 | -29.4% | 607,162 | -12.8% | 1.58% | -30.2% |
| AGEN | Sell | AGENUS INC | $12,449,000 | -2.0% | 3,183,828 | -5.5% | 1.57% | -3.1% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $12,131,000 | -37.1% | 230,842 | -45.7% | 1.53% | -37.8% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $8,305,000 | -33.0% | 2,275,401 | -4.5% | 1.05% | -33.7% |
| VIVE | Sell | VIVEVE MEDICAL INC | $5,712,000 | +1.4% | 795,500 | -10.6% | 0.72% | +0.1% |
| FBIO | Sell | FORTRESS BIOTECH INC | $2,867,000 | -22.3% | 603,657 | -39.4% | 0.36% | -23.1% |
| CLLS | Sell | CELLECTIS - ADRsponsored adr | $2,212,000 | -5.1% | 85,689 | -11.7% | 0.28% | -6.4% |
| AXGT | Sell | AXOVANT SCIENCES LTD | $1,904,000 | -66.9% | 82,087 | -78.7% | 0.24% | -67.3% |
| Sell | NEURODERM LTD | $1,331,000 | -91.5% | 44,516 | -92.5% | 0.17% | -91.6% | |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $832,000 | -82.3% | 416,230 | -65.1% | 0.10% | -82.6% |
| ARRY | Sell | ARRAY BIOPHARMA INCcall | $587,000 | +50.5% | 500,000 | -42.0% | 0.07% | +48.0% |
| CLVS | Exit | CLOVIS ONCOLOGY INCcall | $0 | – | -125,800 | -100.0% | -0.03% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -227,399 | -100.0% | -0.18% | – | |
| BLCM | Exit | BELLICUM PHARMACEUTICALS INC | $0 | – | -125,000 | -100.0% | -0.20% | – |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -121,715 | -100.0% | -0.32% | – |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -456,369 | -100.0% | -0.54% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -165,000 | -100.0% | -0.84% | – |
| AVXS | Exit | AVEXIS INC | $0 | – | -225,370 | -100.0% | -2.19% | – |
| SGEN | Exit | SEATTLE GENETICS INC | $0 | – | -450,000 | -100.0% | -3.61% | – |
| LBIO | Exit | LION BIOTECHNOLOGIES INC | $0 | – | -4,551,343 | -100.0% | -4.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.